tradingkey.logo

BioLife Solutions Inc

BLFS
View Detailed Chart

26.243USD

+0.658+2.57%
Market hours ETQuotes delayed by 15 min
1.26BMarket Cap
LossP/E TTM

BioLife Solutions Inc

26.243

+0.658+2.57%
Intraday
1m
30m
1h
D
W
M
D

Today

+2.57%

5 Days

-0.93%

1 Month

+7.82%

6 Months

+1.25%

Year to Date

+1.09%

1 Year

+11.91%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-17

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
24 / 207
Overall Ranking
117 / 4723
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 10 analysts
Buy
Current Rating
31.300
Target Price
+20.48%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
BioLife Solutions, Inc. is a supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
Growing
The company is in a growing phase, with the latest annual income totaling USD 82.25M.
Undervalued
The company’s latest PE is -244.88, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 47.71M shares, decreasing 10.17% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 2.89M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

BioLife Solutions, Inc. is a supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
Ticker SymbolBLFS
CompanyBioLife Solutions Inc
CEOMr. Roderick De Greef
Websitehttps://www.biolifesolutions.com/
KeyAI